BioXcel Therapeutics (BTAI) Non-Current Assets (2017 - 2026)

BioXcel Therapeutics' Non-Current Assets history runs 10 years deep, the most recent figure standing at $117000.0 for Q1 2026.

• In Q1 2026, Non-Current Assets fell 85.17% year-over-year to $117000.0; the TTM figure through Mar 2026 stood at $1.3 million (down 68.61% YoY), while the FY2025 annual figure was $231000.0, down 75.53% from the prior year.
• Non-Current Assets was $117000.0 for Q1 2026 at BioXcel Therapeutics, down from $231000.0 in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $3.5 million in Q1 2022 to a low of $117000.0 in Q1 2026.
• Historically, Non-Current Assets has averaged $1.6 million across 5 years, with a median of $1.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets increased 13.63% in 2022, then sank 85.17% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $3.0 million in 2022, then tumbled by 47.77% to $1.6 million in 2023, then plunged by 39.45% to $944000.0 in 2024, then slumped by 75.53% to $231000.0 in 2025, then slumped by 49.35% to $117000.0 in 2026.
• The last three Non-Current Assets figures came in at $117000.0 (Q1 2026), $231000.0 (Q4 2025), and $389000.0 (Q3 2025), per Business Quant data.